


Microbiological Identification using

MALDI-TOF

and Tandem

Mass Spectrometry

Industrial and Environmental Applications



Edited by

Haroun N. Shah • Saheer E. Gharbia • Ajit J. Shah
Erika Y. Tranfield • K. Clive Thompson

WILEY

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[Dedication Page](#)

[List of Contributors](#)

[Preface](#)

[1 Progress in the Microbiological Applications of Mass Spectrometry: from Electron Impact to Soft Ionization Techniques, MALDI-TOF MS and Beyond](#)

[1.1 Introduction](#)

[1.2 The Dawn of MALDI-TOF MS: Establishing Proof of Concept for Diagnostic Microbiology](#)

[1.3 Linear/Reflectron MALDI-TOF MS to Tandem Mass Spectrometry](#)

[1.4 The Application of MALDI-MS Profiling and Imaging in Microbial Forensics: Perspectives](#)

[1.5 Hydrogen/Deuterium Exchange Mass Spectrometry in Microbiology](#)

[1.6 The Omnitrap, a Novel MS Instrument that Combines Many Applications of Mass Spectrometry](#)

[References](#)

[2 Machine Learning in Analysis of Complex Flora Using Mass Spectrometry](#)

[2.1 Introduction](#)

[2.2 An Improved MALDI-TOF MS Data Analysis Pipeline for the Identification of Carbapenemase-producing *Klebsiella pneumoniae*](#)

[2.3 Detection of Vancomycin-Resistant *Enterococcus faecium*](#)

[2.4 Detection of Azole Resistance in *Aspergillus fumigatus* Complex Isolates](#)

[2.5 Peak Analysis for Discrimination of *Cryptococcus neoformans* Species Complex and their Interspecies Hybrids](#)

[2.6 Conclusions](#)

[References](#)

[3 Top-down Identification of Shiga Toxin \(and Other Virulence Factors and Biomarkers\) from Pathogenic *E. coli* using MALDI-TOF/TOF Tandem Mass Spectrometry](#)

[3.1 Introduction](#)

[3.2 Decay of Metastable Peptide and Protein Ions by the Aspartic Acid Effect](#)

[3.3 Energy Deposition during Desorption/Ionization by MALDI](#)

[3.4 Protein Denaturation and Fragmentation Efficiency of PSD](#)

[3.5 Arginine and its Effect on Fragment Ion Detection and MS/MS Spectral Complexity](#)

[3.6 Inducing Gene Expression in Wild-type Bacteria for Identification by Top-Down Proteomic Analysis](#)

[3.7 Top-down Proteomic Identification of B-Subunit of Shiga Toxin from STEC Strains](#)

[3.8 Furin-digested Shiga Toxin and Middle-down Proteomics](#)

[3.9 Top-down Identification of an Immunity Cognate of a Bactericidal Protein Produced from a STEC Strain](#)

[3.10 LC-MALDI-TOF/TOF](#)

3.11 Conclusions

References

4 Liquid Atmospheric Pressure (LAP) – MALDI MS(/MS). Biomolecular Profiling for Large-scale Detection of Animal Disease and Food Adulteration and Bacterial Identification

4.1 Introduction

4.2 Background to LAP-MALDI MS

4.3 Bacterial Identification by LAP-MALDI MS

4.4 Food Adulteration and Milk Quality Analysis by LAP-MALDI MS

4.5 Animal Disease Detection by LAP-MALDI MS

4.6 Antibiotic Resistance Detection of Microbial Consortia by LAP-MALDI MS

4.7 Future Directions for LAP-MALDI MS

Applications

References

5 Development of a MALDI-TOF Mass Spectrometry Test for Viruses

5.1 Introduction

5.2 Understanding the Systems Biology of the Virus and Viral Infections

5.3 Understanding the Nature of Viral Proteins and Molecular Biology

5.4 Virion Protein Solubilization and Extraction

5.5 Sampling and Virion Enrichment

5.6 Peak Identification: Quantification and Bioinformatics

5.7 Promise and Pitfalls of Machine Learning Bioinformatics

[5.8 Accelerating MALDI-TOF Assay Protocol Development Using Pseudotypes/pseudoviruses](#)

[5.9 Understanding the Operational Parameters of your MALDI-TOF MS](#)

[5.10 Understanding the Operational Requirements of the Clinical Testing Laboratory: Validation and International Accreditation](#)

[5.11 MALDI-TOF MS Screening Test for SARS-CoV-2s](#)

[5.12 CLIA LDT Validation of a MALDI-TOF MS Test for SARS-CoV-2](#)

[References](#)

[6 A MALDI-TOF MS Proteotyping Approach for Environmental, Agricultural and Food Microbiology](#)

[6.1 Introduction](#)

[6.2 Serotyping of *Salmonella enterica* Subspecies *enterica*](#)

[6.3 Discrimination of the Lineages of *Listeria monocytogenes* and Species of *Listeria*](#)

[6.4 Discrimination of the *Bacillus cereus* Group and Identification of Cereulide](#)

[6.5 Identification of Alkylphenol Polyethoxylate-degrading Bacteria in the Environment](#)

[6.6 Conclusions and Future Perspectives](#)

[References](#)

[7 Diversity, Transmission and Selective Pressure on the Proteome of *Pseudomonas aeruginosa*](#)

[7.1 Introduction: Diversity](#)

[7.2 Transmission](#)

[7.3 Selective Pressures on the Proteome](#)

[7.4 Conclusions on Studies of the Proteome](#)

[7.5 Genomic Studies on *Pseudomonas aeruginosa* Strains Revealing the Presence of Two Distinct Clades](#)

[7.6 Final Conclusions](#)

[References](#)

[8 Characterization of Biodegradable Polymers by MALDI-TOF MS](#)

[8.1 Introduction](#)

[8.2 Structural Characterization of Poly\(\$\epsilon\$ -caprolactone\) Using MALDI-TOF MS](#)

[8.3 Biodegradation Profiles of a Terminal-modified PCL Observed by MALDI-TOF MS](#)

[8.4 Bacterial Biodegradation Mechanisms of Non-ionic Surfactants](#)

[8.5 Advanced Molecular Characterization by High-resolution MALDI-TOF MS Combined with KMD Analysis](#)

[8.6 Structural Characterization of High-molecular-weight Biocopolyesters by High-resolution MALDI-TOF MS Combined with KMD Analysis](#)

[References](#)

[9 Phytoconstituents and Antimicrobiological Activity](#)

[9.1 Introduction to Phytochemicals](#)

[9.2 An Application to Bacteriology](#)

[9.3 Applications to Parasitology](#)

[9.4 A Proteomic Approach: *Leishmania* Invasion of Macrophages](#)

[9.5 Intracellular *Leishmania* Amastigote Spreading between Macrophages](#)

[9.6 Potential Virus Applications](#)

[Acknowledgements](#)

References

10 Application of MALDI-TOF MS in Bioremediation and Environmental Research

10.1 Introduction

10.2 Microbial Identification: Molecular Methods and MALDI-TOF MS

10.3 Combination of MALDI-TOF MS with Other Methods for the Identification of Microorganisms

10.4 Application of MALDI-TOF MS in Environmental and Bioremediation Studies

10.5 Microbial Products and Metabolite Activity

10.6 Challenges of Environmental Applications

10.7 Opportunities and Future Outlook

10.8 Conclusions

References

11 From Genomics to MALDI-TOF MS: Diagnostic Identification and Typing of Bacteria in Veterinary Clinical Laboratories

11.1 Introduction

11.2 Genomics

11.3 Defining Bacterial Species Through Genomics

11.4 MALDI-TOF MS

11.5 Combining Genomics with MALDI-TOF MS to Classify Bacteria at the Subspecies Level

11.6 Data Exploration with MALDI-TOF MS

11.7 Validation of Typing Strategies

11.8 Future Directions

References

12 MALDI-TOF MS Analysis for Identification of Veterinary Pathogens from Companion Animals and

Livestock Species

12.1 Veterinary Diagnostic Laboratories and the MALDI-TOF Clinical Microbiology Revolution¹

12.2 Identification of *Campylobacter* spp. and *Salmonella* spp. in Routine Clinical Microbiology Laboratories²

12.3 Identification and Differentiation of Mycoplasmas Isolated from Animals³

References

13 MALDI-TOF MS: from Microbiology to Drug Discovery

13.1 Introduction

13.2 Microbial Fingerprinting

13.3 Mammalian Cell Fingerprinting

13.4 Drug Discovery Using MALDI-TOF

13.5 Limitations/Challenges, Future Outlook, and Conclusions

13.6 Future Outlook/Conclusions

References

14 Rapid Pathogen Identification in a Routine Food Laboratory Using High-throughput MALDI-TOF Mass Spectrometry

14.1 Introduction

14.2 MALDI-TOF MS in Food Microbiology

14.3 Review of Existing Confirmation Techniques and Comparison to MALDI-TOF MS

14.4 Strain Typing Using MALDI-TOF MS

14.5 Verification Trial

14.6 Limitations of MALDI-TOF MS Strain Typing and Future Studies

[14.7 *Listeria* Detection by MALDI-TOF MS](#)

[14.8 Trial Sample Preparation Procedure](#)

[14.9 Initial Trial](#)

[14.10 Limit of Detection Trial](#)

[14.11 Method Optimization, Further Prospects, and Conclusions](#)

[References](#)

[15 Detection of Lipids in the MALDI Negative Ion Mode for Diagnostics, Food Quality Control, and Antimicrobial Resistance](#)

[15.1 Introduction](#)

[15.2 Applications of Lipids in Clinical Microbiology. Diagnostics](#)

[15.3 Applications of the Detection of Lipids in Negative Ion Mode MALDI-MS in Cancer Studies](#)

[15.4 Applications of the Detection of Lipids and MALDI-MS in Alzheimer's Disease Studies](#)

[15.5 Applications of MALDI in Negative Ion Mode and the Detection of Lipids in Toxicology.](#)

[15.6 Lipids and MALDI Negative Ion Mode for Food Fraud Detection](#)

[15.7 Conclusions and Future Development of Lipids and their Detection in MALDI in Negative Ion Mode](#)

[Acknowledgments](#)

[References](#)

[16 Use of MALDI-TOF MS in Water Testing Laboratories](#)

[16.1 Introduction](#)

[16.2 Application in a Drinking Water Laboratory.](#)

[16.3 Application in Water Hygiene and Environmental Laboratory Testing](#)

[16.4 Potential Application for *Cryptosporidium* Identification](#)

[References](#)

[17 A New MALDI-TOF Database Based on MS Profiles of Isolates in Icelandic Seawaters for Rapid Identification of Marine Strains](#)

[17.1 Introduction](#)

[17.2 Selection and Cultivation of the Strains](#)

[17.3 Genotypic Identification](#)

[17.4 MALDI-TOF MS Data Acquisition and Database Creation](#)

[17.5 Verification of the Accuracy of the Home-made Database](#)

[17.6 Conclusions](#)

[Funding](#)

[References](#)

[18 MALDI-TOF MS Implementation Strategy for a Pharma Company Based upon a Network Microbial Identification Perspective](#)

[18.1 Introduction](#)

[18.2 Regulatory Requirements/Guidance for Microbial Identification](#)

[18.3 Strategic Approaches to MALDI-TOF Implementation Within the Modern Microbial Methods Framework](#)

[18.4 Conclusions](#)

[18.A Appendix](#)

[References](#)

[19 MALDI-TOF MS – Microbial Identification as Part of a Contamination Control Strategy for Regulated Industries](#)

[19.1 Industry Perspective](#)

[19.2 Technical Perspective](#)

[19.3 MALDI-TOF MS Microbial Identification Workflow at a High-throughput Laboratory](#)

[19.4 MALDI-TOF MS Library Development and Coverage](#)

[19.5 Comparison of MALDI-TOF MS with Other Microbial Identification Methods](#)

[19.6 Future Perspectives](#)

[References](#)

[20 Identification of Mold Species and Species Complex from the Food Environment Using MALDI-TOF MS](#)

[20.1 Fungal Taxonomy](#)

[20.2 Impact of Molds in Food](#)

[20.3 Identification of Fungi](#)

[20.4 Identification of Foodborne Molds Using MALDI-TOF MS](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 1

[Table 1.1 MALDI-TOF MS data obtained from Bruker Microbiology & Diagnostics...](#)

[Table 1.2 A cross-section of the non-clinical areas in which MALDI-TOF MS i...](#)

Chapter 2

[Table 2.1 Discrimination of VSE from VRE isolates and, within the latter gr...](#)

[Table 2.2 Accuracy of internal validation for the classification of VanA an...](#)

Chapter 4

[Table 4.1 Confusion matrix for the detection of 5% cow's milk in goat's mil...](#)

[Table 4.2 Confusion matrix for the detection of 10% cow's milk in goat's mi...](#)

Chapter 5

[Table 5.1 Global viral disease outbreaks since the beginning of the twentie...](#)

[Table 5.2 \(a\) 1. Limit of detection based on biological assay \(PFU\) of SARS...](#)

[Table 5.3 Determination of interfering substance and cross-reaction with ot...](#)

[Table 5.4 Tabulated results of a comparison of the MALDI-TOF MS test for SA...](#)

[Table 5.5 Tabulated determination of repeat positive samples and repeat neg...](#)

[Table 5.6 Composite tabulation of storage stability of gargle-saliva spiked...](#)

Chapter 6

[Table 6.1 Primers used for sequencing ribosomal proteins encoded in the *S10*...](#)

[Table 6.2 Theoretical \$m/z\$ \(\$\[M+H\]^{\pm}\$ \) values of selected biomarkers for seroty...](#)

[Table 6.3 Summary of serotyping results of 116 *S. enterica* strains by Strai...](#)

[Table 6.4 Results of *Listeria* species from fingerprinting analysis with SAR...](#)

[Table 6.5 Theoretical *m/z* values of ribosomal subunit proteins for proteoty...](#)

[Table 6.6 Ribosomal protein profile matching for phylogenetic analysis of *P...*](#)

[Table 6.7 Masses of ribosomal subunit proteins for proteotyping of *M. thiog...*](#)

Chapter 7

[Table 7.1 Proteins of notable fold increase in abundance in response to tob...](#)

Chapter 9

[Table 9.1 Best fit of glycan fragments.](#)

[Table 9.2 Differentially expressed proteins identified by MALDI-TOF followi...](#)

Chapter 10

[Table 10.1 Comparison of molecular methods and MALDI-TOF MS for microbial i...](#)

[Table 10.2 Examples of the application of MALDI-TOF MS in the identificatio...](#)

Chapter 12

[Table 12.1 Examples of important and well-recognized diseases of livestock,...](#)

Chapter 13

[Table 13.1 Identification of marine bacteria from North Sea ballast water....](#)

Chapter 14

[Table 14.1 Isolates used in the verification trial and their details.](#)

[Table 14.2 *Listeria monocytogenes* strain typing peak comparison.](#)

[Table 14.3 *Escherichia coli* strain typing peak comparison.](#)

[Table 14.4 Results for the *Listeria monocytogenes* strain typing trial.](#)

[Table 14.5 Results for the *Escherichia coli* strain typing trial.](#)

[Table 14.6 Twenty-four- and forty-eight-hour results of detection by MALDI-...](#)

[Table 14.7 ISO results for *Listeria* spp. detection.](#)

[Table 14.8 MALDI-TOF MS detection and ISO detection results for 1 cfu/25 g ...](#)

Chapter 15

[Table 15.1 MALDI matrices and their applications in negative ion mode.](#)

Chapter 16

[Table 16.1 Identification of spiked samples for a range of organisms typica...](#)

[Table 16.2 Comparison of MALDI-TOF confirmation method and reference method...](#)

[Table 16.3 Mean confidence score value results \(\$n\$ = minimum of 4\) for a ran...](#)

[Table 16.4 Variables to be assessed during validation.](#)

[Table 16.5 Additional growth media assessed to be suitable.](#)

[Table 16.6 Repeatability and reproducibility exercise results.](#)

[Table 16.7 Results of colony confirmation using traditional and MALDI-TOF t...](#)

[Table 16.8 Outcome of efficiency and significant difference assessments.](#)

[Table 16.9 The most recent *Cryptosporidium* outbreaks linked to public water...](#)

Chapter 17

[Table 17.1 Background information on the strains at the start of the study....](#)

[Table 17.2 Genotypic and MALDI-TOF MS in comparison with MBT DB-7854 MSP \(B...](#)

[Table 17.3 Background information and MALDI Biotyper identification results...](#)

Chapter 18

[Table 18.1 Comparison of microbiological identification technologies.](#)

[Table 18.2 Pros and cons of implementing a CoE program.](#)

[Table 18.3 Business case considerations.](#)

[Table 18.4 Comparison of the validation core elements: EP versus USP.](#)

[Table 18.5 Overview of the required validation parameters in EP 5.1.6 \[18\],...](#)

[Table 18.A.1 Microbial identification requirements and guidance.](#)

Chapter 20

[Table 20.1 The main filamentous fungi used to manufacture fermented foods a...](#)

[Table 20.2 Examples of mycotoxins, producing fungi and host plants.](#)

[Table 20.3 Example of an experimental plan for database-building for one sp...](#)

List of Illustrations

Chapter 1

[Figure 1.1 Transition of the genus *Bacteroides* \(Mol.% G+C = 28-61%\) to more ...](#)

[Figure 1.2 Lipids most commonly analysed in *Bacteroides* and other bacteria d...](#)

[Figure 1.3 Competing MALDI-TOF MS technologies in the mid-1990s and matrices...](#)

[Figure 1.4 Milestones in the development and application of various MALDI-TO...](#)

[Figure 1.5 Emergence of the genus *Porphyromonas* from the immensely complex g...](#)

[Figure 1.6 A subset of data from Figure 1.5 is expanded within a narrower ra...](#)

[Figure 1.7 Comparison of the MS spectrum of *Staphylococcus sciuri* from the e...](#)

[Figure 1.8 DDA-MS and DIA-MS for discover and targeted proteomics workflows....](#)

[Figure 1.9 Examples of MALDI MS imaging in microbiology. \(a\) Alkyl quinoline...](#)

[Figure 1.10 \(i\) The protein is incubated in D₂O for different time periods, ...](#)

[Figure 1.11 A mechanical engineering section of a common configuration of th...](#)

[Figure 1.12 Schematic and practical implementation of the Omnitrap platform....](#)

[Figure 1.13 The ion activation network accessible for multiple fragmentation...](#)

[Figure 1.14 The Omnitrap platform implementation at the trailing end of a Th...](#)

[Figure 1.15 \(a\) Annotated MS² ECD mass spectrum of ubiquitin generated by ex...](#)

Chapter 2

[Figure 2.1 The different steps involved in formulation of the study, the rep...](#)

[Figure 2.2 Standard operating procedure for evaluation of the biological and...](#)

[Figure 2.3 Reproducibility stage. \(a\) Initial study. Coefficients of variati...](#)

[Figure 2.4 Distance plot of PLS-DA machine-learning algorithm for the discri...](#)

[Figure 2.5 Discrimination of *Aspergillus fumigatus* sensu stricto from the cr...](#)

[Figure 2.6 Clustering of cryptic species from the *Aspergillus fumigatus* comp...](#)

[Figure 2.7 Differentiation of susceptible \(\$n = 91\$ \) and resistant \(\$n = 40\$ \) *As...*](#)

[Figure 2.8 Classification of the three *Cryptococcus* species by SVM in the on...](#)

Chapter 3

[Figure 3.1 MS/MS-PSD of the singly charged \[M+H\][±] of B-subunit of Shiga toxin...](#)

[Figure 3.2 MS/MS-PSD of the singly charged \[M+H\][±] of YahO protein ion. Avera...](#)

[Figure 3.3 MS/MS-PSD of the singly charged \[M+H\][±] of CspE protein ion. Avera...](#)

[Figure 3.4 MS/MS-PSD of the singly charged \[M+H\][±] of CsbD protein ion. The b...](#)

[Figure 3.5 Agar plates of *Escherichia coli* O157:H7 strain EDL933 cultured ov...](#)

[Figure 3.6 MS/MS-PSD of the singly charged \[M+H\][±] of the disulfide bond-inta...](#)

[Figure 3.7 MS/MS-PSD of the singly charged \[M+H\][±] of the disulfide bond-redu...](#)

[Figure 3.8 Three-dimensional image of the AB₅ Shiga holotoxin. The five iden...](#)

[Figure 3.9 Full amino acid sequence of the A-subunit of Shiga toxin 2 outlin...](#)

[Figure 3.10 Detection of the singly charged \[M+H\][±] A2 protein fragment of th...](#)

[Figure 3.11 MS/MS-PSD of the A2 protein ion. A2 sequence shown above with ba...](#)

[Figure 3.12 Top panel: MS analysis of *E. coli* O113:H21 strain RM7788 culture...](#)

[Figure 3.13 A portion of the genome of a plasmid carried by *E. coli* O113:H21...](#)

Chapter 4

[Figure 4.1 LAP-UV-MALDI mass spectrum of MK-bradykinin \(sequence: MKRPPGFSPF...](#)

[Figure 4.2 LAP-UV-MALDI CID MS/MS spectra of the doubly \(a\) and triply \(b\) p...](#)

[Figure 4.3 \(a\) Schematic of a LAP-UV-MALDI source. \(b\) Close-up image of the...](#)

[Figure 4.4 LAP-UV-MALDI MS spectrum \(\$m/z\$ 100–2000\) obtained by acquiring dat...](#)

[Figure 4.5 AP-UV-MALDI mass spectra of *E. coli* obtained from a solid \(a\) and...](#)

[Figure 4.6 LAP-UV-MALDI mass spectra of the lipid profiles of several bacter...](#)

[Figure 4.7 LAP-UV-MALDI MS/MS spectrum of the precursor ion at \$m/z\$ 726.5, de...](#)

[Figure 4.8 Plot of the PCA data points for the first three principal compone...](#)

[Figure 4.9 \(a\) Linear discriminant analysis \(LDA\) plot obtained with Abstrac...](#)

[Figure 4.10 LAP-MALDI mass spectra of cow's milk \(a\) and goat's milk \(b\), ea...](#)

[Figure 4.11 Workflow for the sample preparation and LAP-MALDI MS analysis of...](#)

[Figure 4.12 Total ion chromatogram recorded for 50 separate milk samples ana...](#)

[Figure 4.13 \(a\) LAP-MALDI mass spectrum of dairy milk, displaying the \$m/z\$ ra...](#)

[Figure 4.14 \(a, b\) Graphic representation \(biplot\) of the LDA model and the ...](#)

[Figure 4.15 LAP-MALDI-CID MS/MS spectra of MS profile ion peaks. MS/MS spect...](#)

[Figure 4.16 Detection of \$\beta\$ -lactamase activity in bovine milk with spiked \(le...](#)

Chapter 5

[Figure 5.1 Periods of excess deaths corresponding to viral epidemics/pandemi...](#)

[Figure 5.2 Illustration of the limited composition of unique proteins found ...](#)

[Figure 5.3 Molecular cellular pathology of SARS-CoV-2 infection. \(a\) Schemat...](#)

[Figure 5.4 Process of virion enrichment within a biological sample and extra...](#)

[Figure 5.5 Illustration of mass spectral peak spreading due to increased com...](#)

[Figure 5.6 Graphic illustration of production of “pseudotype virus” expressi...](#)

[Figure 5.7 Illustration of full profile of virion proteins detected by MALDI...](#)

[Figure 5.8 Spectra illustrating how endogenous sample proteins from gargle-s...](#)

[Figure 5.9 Example of an asymptomatic SARS-CoV-2-positive gargle-saliva samp...](#)

[Figure 5.10 MALDI-TOF MS test incorporating IgA as a clinical feature in cli...](#)

Chapter 6

[Figure 6.1 Concept of the *S10*-GERMS method for bacterial proteotyping. The t...](#)

[Figure 6.2 Cluster analysis of *S. enterica* subsp. *enterica* by Strain Solutio...](#)

[Figure 6.3 Biomarker hit profiles and classification results of 116 *S. enter...*](#)

[Figure 6.4 Sample preparation process for detecting the biomarker with high ...](#)

[Figure 6.5 Mass spectral comparison of SodA for *S. Typhimurium* \(NBRC13245\),](#)

[Figure 6.6 The theoretical \$m/z\$ values of the candidate ribosomal proteins in...](#)

[Figure 6.7 The specific set of \$m/z\$ values for eight biomarkers in proteotypi...](#)

[Figure 6.8 Phylogenetic tree based on a set of four biomarkers \[91, 92\]. The...](#)

[Figure 6.9 MALDI mass spectra of representative observed biomarkers for OPEO](#)

Chapter 7

[Figure 7.1 Hierarchical cluster analysis of phenotypical profiles of *P. aeru...*](#)

[Figure 7.2 Antibiotic resistance in *P. aeruginosa* isolates from CF, environm...](#)

[Figure 7.3 Top ranking peaks for source classification of *P. aeruginosa* by M...](#)

[Figure 7.4 Transmission routes of *P. aeruginosa*. *P. aeruginosa* can be transm...](#)

[Figure 7.5 A bootstrapped maximum likelihood tree for 57 genome-sequenced *P...*](#)

[Figure 7.6 \(a\) Partial sequence alignment of the LysR family transcriptional...](#)

Chapter 8

[Figure 8.1 Mass spectra of PCL and assigned chemical structures.](#)

[Figure 8.2 Size exclusion chromatography \(SEC\)/MALDI-TOF MS analysis of PCL....](#)

[Figure 8.3 Typical MALDI mass spectra of original PCL sample \(a\) and PCL sam...](#)

[Figure 8.4 Typical MALDI mass spectra of the OPEO extracts after incubation ...](#)

[Figure 8.5 Enlarged MALDI mass spectra \(trimer region\) of the biodegraded OP...](#)

[Figure 8.6 Typical MALDI mass spectra of the biodegraded surfactants. \(a\) NP...](#)

[Figure 8.7 Spiral ion trajectory system of JMS-S3000 Spiral TOF.](#)

[Figure 8.8 Strategy for the compositional characterization of the PEO "monos...](#)

[Figure 8.9 Mass spectrum of P\(3HB-co-3HV\) processed by the on-plate degradat...](#)

[Figure 8.10 KMD plot and DP plot of P\(3HB-co-3HV\) processed by the on-plate...](#)

Chapter 9

[Figure 9.1 Phytochemicals.](#)

[Figure 9.2 MALDI spectrum of pure allicin.](#)

[Figure 9.3 MALDI mass spectra recorded as described in the text: \(a\) *S. aure...*](#)

[Figure 9.4 MALDI mass spectra. Expanded region 1100-2000 \$m/z\$ of the treated ...](#)

[Figure 9.5 2D-DIGE images of the same gel which include the three dyes and t...](#)

[Figure 9.6 Relative distribution of the proteins differentially expressed du...](#)

[Figure 9.7 Common viruses and tested phytochemical treatments.](#)

Chapter 10

[Figure 10.1 A schematic overview of MALDI-TOF MS application for the identif...](#)

[Figure 10.2 Microbial identification methods.](#)

[Figure 10.3 General workflow of DNA sequencing for the identification of bac...](#)

[Figure 10.4 Overview of the combination of MS with other methods for microbi...](#)

Chapter 11

[Figure 11.1 Identification of bacteria genotypes or subtypes, virulence, or ...](#)

[Figure 11.2 Workflow for MALDI-TOF MS biomarker-based typing assays. The bla...](#)

Chapter 12

[Figure 12.1 Bacterial culture and antimicrobial susceptibility testing workf...](#)

[Figure 12.2 \(a\) Overlays of MALDI-TOF mass spectra using FlexAnalysis 3.4 so...](#)

Chapter 13

[Figure 13.1 Comparison of different microalgae MALDI-TOF mass spectral patte...](#)

[Figure 13.2 Mammalian MALDI-TOF MS assays workflow. \(a\) Cell culture/treatme...](#)

[Figure 13.3 CTP synthetase assay using MALDI-TOF MS. Wild-type \(WT\) CTPs \(A\)...](#)

Chapter 14

[Figure 14.1 MALDI-TOF MS spectra for a bacterial test standard sample.](#)

[Figure 14.2 Example workflow for *Salmonella* detection using conventional cul...](#)

[Figure 14.3 Overlaid spectra of two wild-type *E. coli* isolates.](#)

Chapter 15

[Figure 15.1 Proposed workflow using MALDI in positive and negative ion modes...](#)

Chapter 16

[Figure 16.1 Identification process using MALDI-TOF \(MALDI Biotyper, Bruker M...](#)

[Figure 16.2 *Legionella* analytical process, including confirmatory approaches...](#)

[Figure 16.3 2 × 2 diagrammatic representation of colony confirmation outcome...](#)

Chapter 17

[Figure 17.1 Different spectra of strain ISCAR-5297 belonging to *Halomonas*, o...](#)

[Figure 17.2 Repartition of identity percentages of all strains found with th...](#)

[Figure 17.3 Repartition of the number of spectra used per strain-specific MS...](#)

[Figure 17.4 Dendrogram with the 51 marine bacterial strains from the in-hous...](#)

Chapter 18

[Figure 18.1 Microbial identification techniques.](#)

[Figure 18.2 Implementation strategy.](#)

[Figure 18.3 MALDI-TOF in the overall identification process flow.](#)

[Figure 18.4 Typical quality risk management process \[16\].](#)

[Figure 18.5 Typical qualification/validation pathway.](#)

Chapter 19

[Figure 19.1 Conceptual image of a CCS, which consists of a planned set of co...](#)

[Figure 19.2 Workflow for processing samples for microbial identification by ...](#)

[Figure 19.3 \(a, b\) Identification by method \(a\) and distribution of these id...](#)

[Figure 19.4 \(a, b\) Identification by method \(a\) and distribution of these id...](#)

[Figure 19.5 Neighbor-joining phylogenetic tree based on the first 500 bp of ...](#)

[Figure 19.6 Key characteristics of a MALDI-TOF MS library impacting an ident...](#)

[Figure 19.7 Impact of targeted library development and optimized threshold f...](#)

[Figure 19.8 Impact of targeted library development and optimized threshold f...](#)

Chapter 20

[Figure 20.1 Meta-analysis showing the frequency of the main filamentous fung...](#)

[Figure 20.2 *Aspergillus brasiliensis* ATCC 16404 spectra obtained at two, fiv...](#)

Microbiological Identification using MALDI-TOF and Tandem Mass Spectrometry

Industrial and Environmental Applications

Edited by

Haroun N. Shah

*Middlesex University
London, UK*

Saheer E. Gharbia

*UK Health Security Agency
London, UK*

Ajit J. Shah

*Middlesex University
London, UK*

Erika Y. Tranfield

*Bruker UK Limited
Coventry, UK*

ubiquitin [34](#), [35](#)
ultra-performance liquid chromatography (UPLC) [15](#)-16
United States Pharmacopeia (USP) [462](#), [465](#), [465-466](#),
[468-469](#), [477](#)
urinary tract infection (UTI) [306](#)-307
user requirement specification (URS) [457](#)

V

VanA/VanB genes [56](#)-59, [57](#), [58](#)
vancomycin-resistant *Enterococcus faecium* [55](#)-59, [57](#),
[58](#)
vancomycin-susceptible *Enterococcus* (VSE) [56](#)-59, [57](#)
veterinary diagnostic laboratories [283](#), [294](#), [303](#)-305,
[317](#)-318
 diagnostic identification and typing of bacteria [283](#)-
 295, [290](#), [293](#)
 MALDI-TOF MS for microbial identification [287](#)-295
 workflow in clinical microbiology laboratory [304](#), [304](#)-
 305

veterinary pathogens [303](#)-321

- antimicrobial resistance, prediction of [307](#)-308
- identification directly from clinical specimens [305](#)-307
- identification of *Campylobacter* spp. and *Salmonella* spp. [309](#)-316
- mycoplasmas [316](#)-320, [317](#),[321](#)
- Pseudomonas aeruginosa* isolates [184](#)-186, [187](#)-188
- veterinary hospital biosecurity and epidemiological surveillance [308](#)-309
- workflow in clinical microbiology laboratory [304](#), [304](#)-305

Vibrio [431](#)

viral proteins

- nature of [121](#), [123](#)
- solubilization and extraction [123](#)

viridans streptococci [306](#)

virion particles [120](#), [121](#)

virulence factors

- connection to genotype [284](#), [291](#)-292
- MALDI-TOF tests for [290](#)
- Mannheimia haemolytica* [291](#)
- Moraxella bovoculi* [291](#)-292
- Pseudomonas aeruginosa* [184](#)-185, [185](#), [191](#), [196](#)
- top-down identification using MALDI-TOF/TOF [71](#)-93
- in veterinary isolates [184](#), [291](#)-292
- see also [Shiga toxins](#)

virus

disease outbreaks 117, [118-119](#), [119](#)

lipid detection in negative ion mode [388](#)

MALDI-TOF MS test development for 117-141

molecular biology [121](#), [123](#)

phytochemical antiviral agents [244-245](#), [245](#)

sampling and virion enrichment [123-125](#), [124](#)

systems biology [120](#)

virus, MALDI-TOF MS test development for 117-141

development acceleration using
pseudotypes/pseudoviruses [128-129](#), [129](#)

machine learning bioinformatics [126-128](#)

operational parameters [130-131](#)

operational requirements of clinical testing laboratory
[131-132](#)

peak identification [125-126](#), [126](#)

sampling and virion enrichment [123-125](#), [124](#)

SARS-CoV-2 screening test [132-141](#)

validation and international accreditation [131-132](#)

virion protein solubilization and extraction [123](#)

VRE (vancomycin-resistant *Enterococcus*) [46](#), [55-59](#), [57](#),
[58](#)

VITEK MS [152](#), [306](#), [508](#)

W

Wallemia sebi [499](#)

wastewater microbiology [415](#)-416
water organisms, targeted MALDI-TOF library for [489](#),
[489](#)
water testing [405](#)-425
 Cryptosporidium [406](#), [408](#), [413](#), [423](#)-425, [424](#)
 drinking water [405](#)-413
 healthcare [416](#)
 introduction [405](#)-408
 Legionella testing [414](#)-415, [415](#)
MALDI-TOF MS and traditional methods compared
[411](#), [411](#)-412, [419](#)-420, [420](#)-[421](#)
MALDI-TOF MS application to drinking water [408](#)-413,
[409](#)
water hygiene and environmental laboratory testing
[413](#)-423
whole genome sequencing (WGS) [73](#)-74, [92](#), [152](#), [154](#),
[161](#), [174](#)-175, [191](#), [255](#), [258](#)-260, [309](#), [315](#)-316, [364](#), [369](#)

y

YahO protein [79](#), [80](#)
yeasts, psychrophilic [266](#)

z

zoonoses [125](#), [141](#), [265](#), [306](#), [308](#)-310, [313](#)